Markers of inflammation in recipients of continuous-flow left ventricular assist devices

ASAIO Journal

Volumn 60, Issue 6, 2014, Pages 657-663

  Grosman Rimon, Liza ^a   McDonald, Michael A ^a   Jacobs, Ira ^a   Tumiati, Laura C ^a   Bar Ziv, Stacey Pollock ^a   Shogilev, Daniel J ^a   Mociornita, Amelia G ^a   Ghashghai, Arash ^a   Chruscinski, Andrzej ^a   Cherney, David Z I ^b   Rao, Vivek ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Chemokines; Cytokines; Inflammation; Left ventricular assist device

Indexed keywords

CARDIOLOGY; HEART; PATHOLOGY;

CONTINUOUS FLOWS; ELEVATED LEVEL; HEALTHY CONTROLS; HEART FAILURE; INFLAMMATORY MEDIATORS; PLASMA LEVELS; PULSATILE PUMP; PULSATILITY;

LEFT VENTRICULAR ASSIST DEVICES;

ACETYLSALICYLIC ACID; AMIODARONE; ATORVASTATIN; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARVEDILOL; CREATININE; CYTOKINE; DIGOXIN; ENALAPRIL; FUROSEMIDE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDRALAZINE; INTERFERON GAMMA INDUCED PROTEIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LACTATE DEHYDROGENASE; LOSARTAN; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; METOPROLOL; MONOCYTE CHEMOTACTIC PROTEIN 1; PRAVASTATIN; RAMIPRIL; SILDENAFIL; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WARFARIN; AUTACOID; BIOLOGICAL MARKER; CHEMOKINE;

ADULT; AGED; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CARDIAC PATIENT; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; INTERNATIONAL NORMALIZED RATIO; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MONOCYTE; NEUTROPHIL COUNT; PRIORITY JOURNAL; ADVERSE EFFECTS; BLOOD; CASE CONTROL STUDY; HEART ASSIST DEVICE; HEART STROKE VOLUME; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHEMOKINES; CYTOKINES; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; INFLAMMATION MEDIATORS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; STROKE VOLUME;

EID: 84923870527     PISSN: 10582916     EISSN: 1538943X     Source Type: Journal    
DOI: 10.1097/MAT.0000000000000129     Document Type: Article

References (44)

1. Masai T, Sawa Y, Ohtake S, et al: Hepatic dysfunction after left ventricular mechanical assist in patients with end-stage heart failure: Role of inflammatory response and hepatic microcirculation. Ann Thorac Surg 73: 549-555, 2002.
2. Caruso R, Trunfio S, Milazzo F, et al: Early expression of pro- and anti-inflammatory cytokines in left ventricular assist device recipients with multiple organ failure syndrome. ASAIO J 56:313-318, 2010.
3. Lappegard KT, Bergseth G, Riesenfeld J, et al: The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. J Biomed Mater Res A 87: 129-135, 2008.
4. Loebe M, Koster A, Sanger S, et al: Inflammatory response after implantation of a left ventricular assist device: Comparison between the axial flow MicroMed DeBakey VAD and the pulsatile Novacor device. ASAIO J 47: 272-274, 2001.
5. Slaughter MS, Rogers JG, Milano CA, et al:, HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 361: 2241-2251, 2009.
6. John R, Kamdar F, Liao K, et al: Low thromboembolic risk for patients with the Heartmate II left ventricular assist device. J Thorac Cardiovasc Surg 136: 1318-1323, 2008.
7. Haudek SB, Taffet GE, Schneider MD, Mann DL: TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. J Clin Invest 117: 2692-2701, 2007.
8. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257: 387-389, 1992.
9. Iwasaki J, Nakamura K, Matsubara H, et al: Relationship between circulating levels of monocyte chemoattractant protein-1 and systolic dysfunction in patients with hypertrophic cardiomyopathy. Cardiovasc Pathol 18: 317-322, 2009.
10. Parissis JT, Adamopoulos S, Venetsanou K, et al: Plasma profiles of circulating granulocyte-macrophage colony-stimulating factor and soluble cellular adhesion molecules in acute myocardial infarction. Contribution to post-infarction left ventricular dysfunction. Eur Cytokine Netw 15: 139-144, 2004.
11. Maekawa Y, Anzai T, Yoshikawa T, et al: Effect of granulocyte-macrophage colony-stimulating factor inducer on left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 44: 1510-1520, 2004.
12. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez M, Ferrer J: Prognostic value of interleukin-8 as a predictor of heart failure in patients with myocardial infarction and percutaneous intervention. Int J Cardiol 111: 158-160, 2006.
13. Takahashi T, Anzai T, Yoshikawa T, et al: Serum C-reactive protein elevation in left ventricular remodeling after acute myocardial infarction - role of neurohormones and cytokines. Int J Cardiol 88: 257-265, 2003.
14. Anker SD, Volterrani M, Egerer KR, et al: Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. QJM 91: 199-203, 1998.
15. Yan G, You B, Chen SP, Liao JK, Sun J: Tumor necrosis factor-alpha downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1-alpha 1. Circ Res 103:591-597, 2008.
16. Segers D, Lipton JA, Leenen PJ, et al: Atherosclerotic plaque stability is affected by the chemokine CXCL10 in both mice and humans. Int J Inflam 2011: 936109, 2011.
17. Greaves DR, Hakkinen T, Lucas AD, et al: Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 21: 923-929, 2001.
18. Hein TW, Singh U, Vasquez-Vivar J, Devaraj S, Kuo L, Jialal I: Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis 206: 61-68, 2009.
19. Wassmann S, Stumpf M, Strehlow K, et al: Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res 94: 534-541, 2004.
20. Cherney DZ, Scholey JW, Sochett E, Bradley TJ, Reich HN. The acute effect of clamped hyperglycemia on the urinary excretion of inflammatory cytokines/chemokines in uncomplicated type 1 DM: A pilot study. Diabetes Care. 34: 177-180, 2011.
21. Rogers JG, Aaronson KD, Boyle AJ, et al: HeartMate II Investigators. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol 55: 1826-1834, 2010.
22. Saito S, Westaby S, Piggot D, et al: End-organ function during chronic nonpulsatile circulation. Ann Thorac Surg 74: 1080-1085, 2002.
23. Welp H, Rukosujew A, Tjan TD, et al:Effect of pulsatile and non-pulsatile left ventricular assist devices on the renin-angiotensin system in patients with end-stage heart failure. Thorac Cardiovasc Surg 58 Suppl 2: S185-S188, 2010.
24. Caprio M, Newfell BG, la Sala A, et al: Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 102: 1359-1367, 2008.
25. Hashikabe Y, Suzuki K, Jojima T, Uchida K, Hattori Y: Aldosterone impairs vascular endothelial cell function. J Cardiovasc Pharmacol 47: 609-613, 2006.
26. Luther JM, Gainer JV, Murphey LJ, et al: Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 48: 1050-1057,2006.
27. Ozawa Y, Kobori H, Suzaki Y, Navar LG: Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions. Am J Physiol Renal Physiol 292: F330-F339, 2007.
28. Ruiz-Ortega M, Ruperez M, Lorenzo O, et al:Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl 82: S12-S22, 2002.
29. Sorescu D: Smad3 mediates angiotensin II- and TGF-beta1-induced vascular fibrosis: Smad3 thickens the plot. Circ Res 98:988-989, 2006.
30. Stumpf C, Lehner C, Yilmaz A, Daniel WG, Garlichs CD: Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. Clin Sci (Lond) 105: 45-50, 2003.
31. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27:1201-1206, 1996.
32. Aukrust P, Ueland T, Lien E, et al: Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 83: 376-382, 1999.
33. Aukrust P, Ueland T, Muller F, et al: Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 97: 1136-1143, 1998.
34. Zhao DX, Hu Y, Miller GG, Luster AD, Mitchell RN, Libby P: Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: Association with cardiac allograft vasculopathy and acute rejection. J Immunol 169: 1556-1560, 2002.
35. Crescioli C, Buonamano A, Scolletta S, et al: Predictive role of pretransplant serum CXCL10 for cardiac acute rejection. Transplantation 87: 249-255, 2009.
36. Haskova Z, Izawa A, Contreras AG, Flynn E, Boulday G, Briscoe DM: Organ-specific differences in the function of MCP-1 and CXCR3 during cardiac and skin allograft rejection. Transplantation 83: 1595-1601, 2007.
37. Gullestad L, Simonsen S, Ueland T, et al: Possible role of proinflammatory cytokines in heart allograft coronary artery disease. Am J Cardiol 84: 999-1003, 1999.
38. Martinez-Dolz L, Almenar L, Reganon E, et al: What is the best biomarker for diagnosis of rejection in heart transplantation? Clin Transplant 23: 672-680, 2009.
39. Pethig K, Heublein B, Kutschka I, Haverich A: Systemic inflammatory response in cardiac allograft vasculopathy: high-sensitive C-reactive protein is associated with progressive luminal obstruction. Circulation 102 19 Suppl 3: III233-III236, 2000.
40. Eisenberg MS, Chen HJ, Warshofsky MK, et al: Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. Circulation 102: 2100-2104, 2000.
41. Corry DC, DeLucia A 3rd, Zhu H, et al:. Time course of cytokine release and complement activation after implantation of the HeartMate left ventricular assist device. ASAIO J 44: M347-M351, 1998.
42. Deng MC, Erren M, Tjan TD, et al: Left ventricular assist system support is associated with persistent inflammation and temporary immunosuppression. Thorac Cardiovasc Surg 47 Suppl 2:326-331, 1999.
43. Bruggink AH, van Oosterhout MF, De Jonge N, Gmelig-Meyling FH, De Weger RA: TNFalpha in patients with end-stage heart failure on medical therapy or supported by a left ventricular assist device. Transpl Immunol 19: 64-68, 2008.
44. Goldstein DJ, Moazami N, Seldomridge JA, et al: Circulatory resuscitation with left ventricular assist device support reduces interleukins 6 and 8 levels. Ann Thorac Surg 63: 971-974, 1997.